Comparative evaluation of anaesthetic efficacy of 0.5 percentage bupivacaine with oral diclofenac potassium vs 0.5 percentage bupivacaine on inferior alveolar nerve block in patients with symptomatic irreversible pulpitis in mandibular first molar A prospective randomized clinical trial

开始日期2026-04-25

申办/合作机构-

NCT07646093

/ CompletedN/AIIT

Development and Preliminary Clinical Evaluation of a Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain Management in Paediatric Patients

**Brief Summary**
This study aimed to develop and conduct a preliminary clinical evaluation of a novel weight-adjusted gelatin-based diclofenac potassium medicated lollipop for the management of postoperative pain following adenotonsillectomy in children. The formulation was designed to improve analgesic adherence by providing a palatable and child-friendly dosage form suitable for oral transmucosal administration. Fifty paediatric patients aged 4 to 12 years undergoing elective adenotonsillectomy received one of three weight-adjusted diclofenac potassium lollipop doses (15 mg, 20 mg, or 30 mg) every 8 hours during the first 24 postoperative hours. The study assessed postoperative pain intensity, product acceptability, rescue analgesic use, and safety. In parallel, the formulation underwent pharmaceutical characterization, including physicochemical and microbiological quality evaluation.

开始日期2025-05-01

申办/合作机构-

IRCT20241220064105N4

/ CompletedN/AIIT

Effectiveness of Diclofenac Potassium Gel with and without Transcutaneous Electrical Nerve Stimulation in Primary Dysmenorrhea

开始日期2025-01-14

申办/合作机构-

100 项与双氯芬酸钾相关的临床结果

登录后查看更多信息

100 项与双氯芬酸钾相关的转化医学

登录后查看更多信息

100 项与双氯芬酸钾相关的专利（医药）

登录后查看更多信息

354

项与双氯芬酸钾相关的文献（医药）

2026-11-01·INTERNATIONAL ENDODONTIC JOURNAL

The Effect of Premedication With Trypsin, Bromelain and Rutoside Combination on Anaesthetic Success and Postoperative Pain in Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial

Article

作者: Nasr, Maha ; Hassan, Nermine

ABSTRACT:

Aim:

Achieving profound pulpal anaesthesia in patients with symptomatic irreversible pulpitis (SIP) remains a significant clinical challenge, as standard inferior alveolar nerve blocks (IANB) frequently fail due to localized inflammation. This clinical trial evaluated the effect of preoperative systemic enzyme therapy [trypsin, bromelain, and rutoside (TBR)] on anaesthetic success and postoperative pain in patients with symptomatic irreversible pulpitis.

Methodology:

In this randomized, triple‐blind, parallel‐arm clinical trial, 124 healthy adults with SIP in a single mandibular molar were randomly allocated (1:1:1:1) to four groups ( n = 31): Group FG (trypsin 100 mg/bromelain 90 mg/rutoside 48 mg), Group DF (diclofenac potassium 50 mg), Group PD (prednisolone 20 mg), or Group PB (placebo). One hour after premedication, a standard IANB (1.8 mL 4% articaine, 1:100 000 epinephrine) was administered. The primary outcome was anaesthetic success, defined as the ability to complete endodontic procedures with no or mild pain (NRS ≤ 3). Secondary outcomes included postoperative pain intensity (NRS 0–10) recorded at 6, 12, 24, 48, 72 h, and 7 days, and rescue analgesic intake.

Results:

Data of all 124 enrolled patients was analysed. Premedication significantly influenced IANB success ( p < 0.001). Group FG (87.1%) and group PD (83.9%) achieved significantly higher success rates than group PB (35.5%); the RR of success for group FG compared to PB was 2.45 (99.17% CI: 1.26, 4.77), and for group PB compared to PD was 0.44 (99.17% CI: 0.22, 0.87). Group FG also showed significantly higher success than group DF RR of success for group DF compared to FG was 0.59 (99.17% CI: 0.36, 0.97). Group FG demonstrated significantly lower postoperative pain scores through 72 h compared to the placebo ( p < 0.05). There were no significant differences in rescue analgesic intake ( p = 0.320) or reported adverse events.

Conclusions:

Premedication with the TBR combination significantly improved the success rate of IANB and reduced postoperative pain in mandibular molars with SIP with clinical efficacy comparable to prednisolone.

Clinical Implications:

Systemic enzyme therapy may offer a viable, natural, and potentially safer alternative to corticosteroids or NSAIDs for enhancing pulpal anaesthesia and managing postoperative pain in symptomatic irreversible pulpitis.

Trial Registration:

ClinicalTrials.gov identifier: NCT06298383

2026-07-27·Cureus Journal of Medical Science

Development and Preliminary Clinical Evaluation of a Novel Gelatin-Based Diclofenac Potassium-Medicated Lollipop for Post-adenotonsillectomy Pain Management in Children: A Prospective Pilot Study

Article

作者: Almeida, Mabel Z ; Veraza, Joseph A ; Veraza, Samira A

Post-adenotonsillectomy pain is among the most clinically significant sources of postoperative morbidity in the paediatric population, and its management at home is frequently undermined by poor adherence to conventional oral analgesic formulations - a consequence of their bitter taste and the mechanical difficulty of swallowing during the acute postoperative period. This biphasic translational study describes the pharmaceutical development and preliminary clinical evaluation of a novel gelatin-carboxymethylcellulose hybrid diclofenac potassium-medicated lollipop, produced in three weight-adjusted paediatric dose strengths (15 mg, 20 mg, and 30 mg). Phase I encompassed iterative formulation optimisation, followed by full physicochemical characterisation - including pH, moisture content, viscosity, and drug content uniformity by high-performance liquid chromatography (HPLC) - and microbiological quality assessment, all conducted in accordance with United States Pharmacopoeia (USP 42) standards. The optimised formulation demonstrated a mean pH of 5.67 ± 0.20, uniform viscosity of 8.0 centipoise, HPLC-confirmed drug content of 100.7-102.9% of the labelled dose across all three strengths, and complete microbiological compliance. Phase II was a prospective clinical pilot study enrolling 50 children aged 4-12 years classified as American Society of Anesthesiologists (ASA) Physical Status I-II. ASA I indicates a healthy patient with no systemic disease, whereas ASA II refers to a patient with mild systemic disease without functional limitation. The lollipop was administered at eight-hour intervals for 24 hours postoperatively. Pain intensity was evaluated using the visual analogue scale (VAS) or Wong-Baker FACES Scale before and one hour after each dose. A consistent, progressive reduction in pain scores was observed across all three dose groups, with pain scores progressively decreasing across all dose groups, reaching minimal or absent pain by the third postoperative assessment. Overall taste and texture acceptability was rated positively by 83% of participants. No adverse events were recorded throughout the observation period. These findings establish the pharmaceutical viability and preliminary clinical promise of this formulation as a child-friendly analgesic vehicle and provide a compelling rationale for a powered randomised controlled trial with pharmacokinetic characterisation.

2026-05-01·FERTILITY AND STERILITY

Expression of concern ‘A randomized controlled trial of oral diclofenac potassium for analgesic control during office hysteroscopy’ [Fertil Steril 2017; 108: e15]

Article

项与双氯芬酸钾相关的新闻（医药）

2026-11-03

·药通社

2毛2 的注射剂，判定为劣药，罚款214倍！

近日，江苏省药监局公示对江苏涟水制药有限公司的行政处罚。该企业一款0.22元/支中标的利巴韦林注射液，尚未上市销售即被判定为劣药，涉案货值仅6996元，罚款高达150万元，罚款倍数约为货值的214倍。这款利巴韦林注射液（1ml:0.1g），在广东联盟常见病慢性病药品接续集采中，与其他企业并列最低中选价0.22元/支。本次被罚批次共计3180盒，折合货值6996元，按10支/盒核算，单价与其中标价一致。值得注意的是，该批次药品标注“未上市销售”，属于企业为产品注册、工艺验证组织的试生产批次。监管部门依据《药品管理法》相关条款，认定其构成生产劣药行为，作出没收全部不合格药品、罚款150万元的处罚。按照法规，货值不足10万元按10万元核定罚款基数，最终形成超高倍数处罚。这已经是该企业2026年第二起同类处罚。此前，企业在双氯芬酸钾片工艺再验证、产品再注册阶段组织试生产，成品溶出度项目检验不合格，同样被认定为劣药，监管没收不合格片剂17862盒。两起案件共性突出：涉案批次均未流入市场，均属于注册相关的验证性生产。连续在工艺验证环节失守，说明企业质量体系存在持续性问题，并非偶发操作失误。追溯监管历史记录，该企业多年前就曾迎来国家局飞检，暴露多项严重GMP缺陷，直接导致其小容量注射剂（含激素类）GMP证书被收回。当时检查发现，利巴韦林等非激素产品直接在激素生产车间安排生产，企业未开展共线风险评估，缺少交叉污染防控措施；生产数据可靠性存疑，洗瓶工序没有测温设备，记录上的温度数值依靠员工手摸估算填写，同时存在不按规程操作等问题。监管当时要求企业全面排查该生产线所有品种批次，从本次处罚结果来看，历史隐患并未得到根治。该案最核心的普法意义在于纠正行业一个常见误区：未上市不等于无需担责。《药品管理法》规范的是生产行为本身，工艺验证、注册试生产同样属于药品生产活动，不能因为不对外销售就放宽标准、降低管控。只要产出不符合法定标准的药品，就属于生产劣药。监管从严执法，也体现了对源头质量风险前置打击的思路，不等不合格药品流向患者，就在生产端及时处置。事件背后，集采低价竞争的矛盾再次凸显。集采初衷是压缩流通虚高价格，让患者获得实惠药品，但持续的低价比拼，容易给中小企业带来成本压力。当报价逼近成本红线，部分企业存在压缩设备投入、简化验证流程、弱化过程质控的冲动。该企业历史飞检暴露出的监测设备缺失、数据不真实等问题，正是成本压力下质量管控让步的典型表现。现阶段集采机制也在持续优化，通过成本核查、低价预警、加大合规检查力度，遏制非理性低价竞标，防范“低价中标、降质生产”。工艺验证是药品质量稳定的前置关口，验证失败意味着工艺条件尚不能稳定产出合格药品。企业连续两次验证批次不合格，反映出整改停留在纸面，产线硬件、人员操作、文件体系没有真正闭环。对药企而言，GMP整改不能只应付检查，共线污染、数据可靠性这类基础性缺陷，长期带病运行，早晚会触发处罚风险。集采常态化之下，低价和质量绝非对立关系。降价的空间来自流通环节，而不是生产端的质量投入。本次214倍货值的重罚，成本远高于短期省下来的质控开支，企业一旦被认定质量失信，还可能面临集采出局、信用降级等连锁后果。对行业而言，这一案例是明确信号：无论商业化生产还是注册验证批次，质量底线没有例外。药企报价需要立足真实成本，理性参与价格竞争，持续夯实质量体系。监管也在持续前移风险关口，从上市后抽检延伸到注册、工艺验证阶段，从源头守住群众用药安全防线。内容参考：中食药集团 ↓⭐关注药通社，洞见行业趋势↓

引进/卖出

2026-04-08

·BioSpace

Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio

-- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence -- -- SYMPAZAN ® Establishes a Neurology Rare Disease Footprint within Cosette -- -- Additional Brands include INDOCIN ® , SPRIX ® , ZIPSOR ® , CAMBIA ® , and OTREXUP ® -- BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (Nasdaq: ASRT). The acquisition expands Cosette’s branded portfolio and adds the U.S. rights to SYMPAZAN ® , a growing, patent-protected asset, further advancing Cosette’s disciplined growth strategy. SYMPAZAN ® (clobazam) oral film is an FDA-approved medicine for the adjunctive treatment of seizures associated with Lennox‐Gastaut Syndrome (LGS), a rare and severe form of epilepsy, in patients 2 years of age or older. SYMPAZAN ® is a growing product with patent protection extending until 2040. As the first and only FDA-approved oral film formulation of clobazam, SYMPAZAN ® addresses an important unmet need for LGS patients and establishes a Neurology rare disease footprint within Cosette’s branded portfolio. “This acquisition reflects Cosette’s strategic approach to expanding our branded portfolio,” said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. “It adds immediate scale through branded, on-market products and includes SYMPAZAN ® , a growing, patent-protected asset in an orphan indication. Just as important, it reinforces our ability to execute strategic transactions propelling our growth. We look forward to successfully integrating these important medicines into Cosette and continuing to make them available for patients and prescribers.” In addition to SYMPAZAN ® , Cosette has acquired the rights to a portfolio that includes Assertio’s branded non-steroidal anti-inflammatory drugs (NSAIDs) treating indications in inflammation, pain management, and migraine: INDOCIN ® (indomethacin), oral suspension INDOCIN ® (indomethacin), suppositories SPRIX ® (ketorolac tromethamine), nasal spray ZIPSOR ® (diclofenac potassium), liquid-filled capsules CAMBIA ® (diclofenac potassium), for oral solution OTREXUP ® (methotrexate), injection for subcutaneous use The agreement includes a transition period during which Assertio and Cosette will transfer responsibilities for the manufacture, supply, and commercialization of these products, including quality assurance, pharmacovigilance, and regulatory matters. Products: Please see Package Insert (PI) for full prescribing information including complete safety information: SYMPAZAN ® (clobazam) oral film: See full prescribing information for important safety information, including Boxed Warning. INDOCIN ® (indomethacin) oral suspension: See full prescribing information for important safety information, including Boxed Warning. INDOCIN ® (indomethacin) suppositories: See full prescribing information for important safety information, including Boxed Warning. SPRIX ® (ketorolac tromethamine) nasal spray: See full prescribing information for important safety information, including Boxed Warning. ZIPSOR ® (diclofenac potassium) liquid-filled capsules: See full prescribing information for important safety information, including Boxed Warning. CAMBIA ® (diclofenac potassium), for oral solution: See full prescribing information for important safety information, including Boxed Warning. OTREXUP ® (methotrexate) injection for subcutaneous use: OTREXUP ® was discontinued by Assertio in August 2025. About Cosette Pharmaceuticals Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine — acquiring, developing, and delivering products that make a difference in patients’ lives. Cosette’s strong growth has been driven by its proven ability to maximize the value of its portfolio through best‑in‑class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies. Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more information, please visit or follow Cosette on LinkedIn . Contacts Cosette Pharmaceuticals Contacts: Cosette Pharmaceuticals media@cosettepharma.com

上市批准并购引进/卖出

2026-03-24

·医药注册申报平台

再注册工艺验证不合格、违反GMP逾期不改正，两药企被罚！

如果您喜欢我们推送的这篇文章欢迎点赞和转发哦~ 课程推荐《请点击蓝色链接阅读全文》课题更新 2026年3月4号支持回放）报名有惊喜 2026年3-4月课题汇总以及往期回放(线上+线下）南美、西亚、中东及非洲国家药品注册流程 2026新规落地：细胞基因治疗产品质量与工艺在临床转化准备与实施培训班 SD专题负责人核心能力提升进阶研修班会议联系人：郑洁13439784562(微信同步）近日，江苏药监局发布对江苏涟水制药有限公司的行政处罚书，该公司为产品再注册及工艺再验证按计划生产了涉案双氯芬酸钾片（未上市销售），后经检验溶出度不合格，判定其违反了《中华人民共和国药品管理法》第九十八条第三款第七项之规定。判处没收劣药双氯芬酸钾片17862盒，没收违法所得没收非法财物的金额：2.6793万元，如下：再注册工艺验证不合格行政相对人名称：江苏涟水制药有限公司行政处罚决定书文号：苏药监淮罚〔2025〕006号违法行为类型：生产劣药违法事实：当事人为产品再注册及工艺再验证按计划生产了涉案双氯芬酸钾片（未上市销售），后经检验，【检查】项下溶出度不合格，其行为违反了《中华人民共和国药品管理法》第九十八条第三款第七项之规定。处罚依据：《中华人民共和国药品管理法》第九十八条、第一百一十七条、《中华人民共和国行政处罚法》第三十二条处罚类别：没收非法财物处罚内容：没收劣药双氯芬酸钾片（批准文号：国药准字H20000638，批号：25052831，规格：50mg）17862盒没收违法所得没收非法财物的金额（万元）：2.6793 违反GMP逾期不改正 2026年03月23日，河北药监局发布了对河北胡氏宇博药业有限公司的处罚通告，该公司因违反GMP且逾期不改正被罚款35万，如下：行政处罚决定书文号：冀药监中药处罚〔2026〕1号案件名称：河北胡氏宇博药业有限公司违反《药品生产质量管理规范》且逾期不改正案违法企业名称或违法自然人姓名：河北胡氏宇博药业有限公司主要违法事实：未遵守《药品生产质量管理规范》且逾期不改正案处罚种类和方式：罚款350000元行政处罚依据：《中华人民共和国药品管理法》第一百二十六条来源：GMP办公室 2026年3-4月线上线下课题汇总线上地点时间（点击蓝色链接阅读全文）线上 3月28-29号疫苗从IND到BLA全生命周期研发注册（中美欧）实操南京 3月27-29号南京-药物质量研究分析方法的高效建立及典型案例分享线上 3月25号本周日开课-小核酸药物非临床研究策略专题培训线上 4月25-26号东盟五国（菲、马、泰、越、印尼）药品注册及出海全流程线上 3月21-22号 3.21-22 -南美、西亚、中东及非洲国家药品注册流程线上 4月10-11号基于OECD原则：计算机化系统在GLP机构的应用及合规保证线上 4月24-25号 2026类器官技术用于新药研发培训-4月24-25日线上 3月28-29号 2026新规落地：细胞基因治疗产品质量与工艺在临床转化准备与实施培训班线上 4月25-26号细胞治疗产品IIT从备案、临床研究到转化应用全链条及818号条例细则深度解析线上 4月25-26号体内CAR-T研发・递送・CMC・临床・注册全流程关键技术专题线上 3月28-29号 SD专题负责人核心能力提升进阶研修班线上 4月25-26号创新药审评难点破解与 CDE 沟通进阶 -非临床 / 临床实战培训班线上 4月18-19号化学创新药IND要点案例分析专题培训班线上 4月18-19号药品微生物质量管理体系合规升级 — 新法规条文深度剖析与实践应用南京 4月24-26号新药研发项目全流程管理实操演练南京 4月21-23号南京-生物发酵工程关键工艺技术及发酵罐本体装备技术精讲专题线上 3月28-29号 MAH制度下半场如何推进《关于加强药品受托生产监督管理工作的公告》执行线上 4月18-19号药物质量研究分析方法的高效建立及典型案例分享无锡 4月23-25号 AI赋能微生物发酵菌种功能预测、设计、构建与改造及工程化技术应用高级研讨班线上 4月25-26号抗体药物靶点科学立项、分子高效发现及结构设计与成药性优化关键技术要点线上 4月25-26号药企生产设备现代维保体系构建及高效实施策略专题培训班线上 4月18-19号实验设计(DoE)在处方与工艺开发中的高级应用培训线上 3月28-29号 2026实验设计（DOE）赋能重组蛋白工艺开发与优化培训班线上 4月18日-19日 AI应用实施||ADC药物从靶点发现到PCC全链条专题线上 4月11-12号 ADC药物研发质量--偶联工艺、载荷稳定性与分析方法开发线上 4月25-26号 ICH M14 + E23 真实世界证据（RWE）注册申报实战培训专题线上 4月18-19号药品微生物质量管理体系合规升级 — 新法规条文深度剖析与实践应用线上 4月28-29号冻干制品从实验室开发到商业化生产的全生命周期质量控制解决方案和实施线上 4月11-13号小分子创新药制剂处方工艺全生命周期开发与质量研究武汉 4月24-26号 2026“第五期新酶设计与酶技术应用”专题培训班的通知线上 4月10-11号基于OECD原则：计算机化系统在GLP机构的应用及合规保证北京 3月28-30号关于举办“权威解读·精准赋能-GB29922-2025《特殊医学用途配方食品通则》落地与厂房设计、生产工艺研讨会”的通3yue 线上 4月11-12号供应商全流程管理北京 3月28-29号权威解读·精准赋能—GB29922-2025《特殊医学用途配方食品通则》落地与厂房设计、生产工艺研讨会杭州 3月27-29号杭州-精益化工管理体系建设与运营扫描下方二维码“报名登记” 郑洁主任：13439784562 微信同号邮箱13439784562@139.com QQ:1135274078 关注微信公众平台获取更多培训信息核课件：有问题请扫描如下二维码添加微信

核酸药物临床申请基因疗法疫苗申请上市

100 项与双氯芬酸钾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00903	-	M02AA15 D11AX18 M01AB05	DBSALT000864

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Cosette Pharmaceuticals, Inc.	2009-06-17
急性疼痛	美国	Cosette Pharmaceuticals, Inc.	2009-06-16
骨关节炎	美国	Novartis Pharmaceuticals Corp.	1993-11-24
原发性痛经	美国	Novartis Pharmaceuticals Corp.	1993-11-24
类风湿关节炎	美国	Novartis Pharmaceuticals Corp.	1993-11-24
疼痛	美国	Novartis Pharmaceuticals Corp.	1993-11-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	临床3期	美国	Novartis Pharmaceuticals Canada, Inc.	2015-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02287376 (CTgov)	临床4期	偏头痛 \| 无先兆偏头痛	25	Diclofenac Potassium	獵築繭鹹網選選淵膚醖(廠鹽選遞網餘簾衊鹽膚) = 窪鬱壓繭廠齋鏇願醖觸構積憲遞蓋鹹襯顧醖選 (鬱鏇膚積廠衊膚選簾艱, 846.208) 更多	-	2017-07-25
NCT02287350 (CTgov)	临床4期	2型糖尿病 \| 急性疼痛 \| 18型肌张力障碍	51	diclofenac potassium oral solution	製觸鹽願範夢遞鬱繭網(廠選製窪餘衊衊齋鑰夢) = 鬱遞鏇壓築衊繭廠遞鹹鏇選鬱膚齋構齋積選繭 (鏇觸鑰鬱顧壓蓋壓艱膚, 297.53) 更多	-	2017-07-11
NCT02476422 (CTgov)	临床3期	术后疼痛	328	Placebo to ibuprofen+Diclofenac potassium (Dilcofenac Potassium + Placebo to Ibuprofen)	壓鹽蓋鏇獵鬱齋獵餘鬱(鹽鹽鏇醖構膚鏇選簾淵) = 壓築繭積範觸築蓋齋窪憲鑰鹹壓鏇膚膚齋艱遞 (襯鏇襯壓顧獵網蓋積鑰, 2.06) 更多	-	2016-10-17
NCT02476422 (CTgov)	临床3期	术后疼痛	328	Placebo to diclofenac potassium+Ibuprofen (Ibuprofen + Placebo to Diclofenac Potassium)	壓鹽蓋鏇獵鬱齋獵餘鬱(鹽鹽鏇醖構膚鏇選簾淵) = 壓糧壓衊範淵築膚鏇鬱憲鑰鹹壓鏇膚膚齋艱遞 (襯鏇襯壓顧獵網蓋積鑰, 2.08) 更多	-	2016-10-17
NCT01982539 (CTgov)	临床4期	急性疼痛	25	Zipsor®	艱選顧積齋壓製鬱簾膚 = 糧夢鏇膚夢壓鹹餘廠壓製膚願壓鬱獵窪壓艱憲 (襯廠鹽顧鏇繭積齋獵鑰, 艱糧糧構憲顧鏇糧襯鑰 ~ 製蓋糧顧簾鹹憲繭願製) 更多	-	2015-05-15
NCT01019980 (CTgov)	临床4期	急性上呼吸道炎症 \| 发热	2	Diclofenac potassium (Diclofenac Potassium)	窪憲範鹹鏇鹹積鹹遞範(鹹襯獵獵淵繭構壓觸膚) = 膚餘鑰艱艱鑰觸齋遞醖構壓艱鏇淵鹽網構構簾 (獵範鑰窪糧鹽鹽繭繭艱, 積願艱遞齋鏇鏇壓繭鑰 ~ 窪壓範蓋餘製網鑰憲顧) 更多	-	2012-11-19
NCT01019980 (CTgov)	临床4期	急性上呼吸道炎症 \| 发热	2	Acetaminophen (Acetaminophen)	窪憲範鹹鏇鹹積鹹遞範(鹹襯獵獵淵繭構壓觸膚) = 觸廠夢餘憲齋網獵簾遞構壓艱鏇淵鹽網構構簾 (獵範鑰窪糧鹽鹽繭繭艱, 鑰廠鏇鏇膚糧淵艱淵願 ~ 鏇顧衊鹽餘壓鏇壓膚製) 更多	-	2012-11-19